2 results
Approved WMOCompleted
The objectives of this study are to compare the safety and efficacy of 2 annual cycles of intravenous (IV) alemtuzumab to 3-times weekly subcutaneous (SC) interferon beta 1a (Rebif*) in patients with active relapsing-remitting multiple sclerosis (…
Approved WMOCompleted
Primary: to compare the OSS concept with RCM in the surgical treatment of BCCs with current standard of care.Secondary: to assess the accuracy (sensitivity and specificity) of diagnosing BCC by comparing RCM with punch biopsy as diagnostic tools.…